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Abstract
Platelets transport and store serotonin at a high concentration in dense granules and 
release it upon activation. Abnormal serotonin concentrations in the blood plasma or 
increased platelet serotonin release promote the development of thrombosis, sepsis, 
allergic asthma, myocardial infarction, and stroke. Consequently, experimental data sug-
gest possible benefits of serotonin receptor blockade or inhibition of platelet serotonin 
uptake in the indicated human diseases. Here, we highlight the current state of basic bio-
logical research regarding the role of platelet serotonin in normal and pathophysiological 
conditions focusing on thrombotic and inflammatory diseases. We also describe the pos-
sible clinical applicability of targeting thrombo-immune-modulatory effects of platelet 
serotonin to treat common health problems.
Keywords: platelets, serotonin, inflammation, thrombosis, selective serotonin reuptake 
inhibitors
1. Introduction
Serotonin (5-HT) is a well-known neurotransmitter, which regulates neural activity and a 
variety of neuropsychological processes [1]. As it has been shown to be involved in the regu-
lation of systemic and cellular functions, alterations in serotonin concentration in the body 
are associated with many different diseases, such as irritable bowel syndrome, restless legs 
syndrome, sudden infant death syndrome, autism, headache, insomnia, anxiety, depression, 
anorexia, schizophrenia, Parkinson’s and Alzheimer’s disease, pulmonary hypertension, and 
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myocardial infarction. 5-HT was first described in 1930 by Vittrorio Erspamer who isolated 
it from enterochromafin cells of the gut [1]. Only a small amount of 5-HT is synthesized in 
brain (5%), whereas 95% is produced by the enterochromafin cells of the gastrointestinal (GI) 
tract. 5-HT is synthesized from the essential amino acid l-tryptophan (TRP) to 5-hydroxy-
tryptophan (5-HTP) by the enzyme l-tryptophan hydroxylase (TPH)-1 in the brain and 
Figure 1. 5-HT biosynthesis and receptor distribution in brain (A) and periphery (B). Serotonin (5-HT), serotonin 
transporter (SERT), monoamine oxidase (MAO), 5-hydroxyindole acetic acid (5-HIAA), 5-hydroxytryptophan (5-HTP), 
tryptophan (TRP), and vesicular monoamine transporter (VMAT). For the details, see the text.
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TPH-2 in the periphery [2, 3]. The activity of these TPH enzymes is the rate-limiting step in 
the production of 5-HT in both organs. After its synthesis in the gastrointestinal tract, 5-HT 
is released into the bloodstream. 5-HT can bind and activate several isoforms of 5-HT recep-
tors expressed throughout the body (Figure 1). 5-HT receptors were identified on different 
blood cells and in the vessel wall including lymphocytes, endothelial, and smooth muscle 
cells, respectively, which can respond to 5-HT under certain physiological conditions. These 
receptors constitute a family of seven different receptor sub-classes: 5-HT
1
 (A-F, P, S), 5-HT
2
 
(A-D), 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7 [3, 4]. All these receptors belong to the GPCR 
superfamily with the exception of 5-HT3 [3], which is a member of nicotinic acetylcholine 
receptor superfamily and is a ligand-gated ion channel.
5-HT can also be taken up from plasma into several cells—such as platelets—via the 5-HT 
transporter (5-HTT, SERT). After uptake, 5-HT can be then stored in vesicles and granules 
through the action of vesicular monoamine transporter (VMAT)-1/2 which is expressed in 
neurons, neuroendocrine cells, and platelets. The largest quantity of serotonin is believed to 
be stored in platelets, from where it can be released upon platelet activation, for example, 
during thrombus formation or inflammatory reactions. Interestingly, chemical precursors of 
5-HT can pass across the blood-brain barrier, but 5-HT cannot, thereby effectively isolating 
the brain 5-HT pool from the periphery and vice versa. In the brain, 5-HT regulates several 
complex networks, such as mood, perception, reward, anger, memory, appetite, attention, 
and sexuality. There are two major routes of 5-HT metabolism, which convert 5-HT to mela-
tonin and 5-HIAA. 5-HT is metabolized by neurons and endothelial cells by monoamine oxi-
dases (MAOs) and the products of this breakdown are then excreted by the kidney [3, 5–7].
Peripheral 5-HT regulates heart development and rate, valvulopathy, pain, nociception, 
embryonic development, vasoconstriction/vasodilatation, blood flow, hemostasis, and many 
other important processes. Platelets are not able to synthesize serotonin, but take it up from 
plasma via 5-HTT, store it in dense granules (via VMAT-1), and release it into the blood dur-
ing their activation. Platelet serotonin has not only well-established autocrine functions dur-
ing platelet activation and thrombus growth but also paracrine functions in the vasculature 
including modulation of endothelial, smooth muscle, and immune cell function.
2. Autocrine-regulatory mechanisms of platelet serotonin
Platelets store 5-HT in their dense granules at millimolar range and secrete it after activation [8]. 
Dense granule and 5-HT release support the recruitment of circulating platelets to preformed 
thrombi, thereby leading to thrombus growth. This process is mediated through the interaction 
between 5-HT and its receptor 5HT
2A 
expressed on circulating platelets. Activated 5-HT
2A
 recep-
tor transduces the signal to G
q
-phospholipase C (PLC) β-signaling cascade. Enhanced PLCβ 
activity results in intracellular Ca2+mobilization from the store through inositol 3-phosphate 
(IP3) receptor and mediates 1,2-diacylglycerol (DAG)-dependent protein kinase C (PKC) acti-
vation, thereby amplifying platelet reactivity (Figure 2).
In addition to the mobilization of cytosolic Ca2+ [9, 10], receptor-ligand interactions are also 
known to regulate 5-HT uptake kinetics. In human platelets, the rise of cytoplasmic Ca2+ in 
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the absence of exocytosis reduces 5-HT transport into the cytoplasm, thereby decreasing 
the release of 5-HT [9]. Interestingly, rabbit platelets activated in the presence of the extra-
cellular Ca2+ chelator ethylene tetraacetic acid also displayed a decrease in 5-HT transport 
activity [11, 12]. Consistently, human platelets treated with the membrane permeant Ca2+  
chelator BAPTA-AM also had reduced 5-HT transport in the presence of extracellular Ca2+ 
[9]. Activation of the Orai1 Ca2+ channel induces a robust Ca2+ influx called store-operated 
Ca2+ entry (SOCE), which is triggered through the release of Ca2+ from intracellular stores. 
Figure 2. Autocrine effects of platelet 5-HT. Activated platelets release 5-HT, thereby amplifying platelet activation and 
the recruitment of circulating platelets. Binding of platelet 5-HT to the 5-HT
2A
 receptor induces activation of PLCβ-
signaling cascade and upstream effectors which support platelet reactivity. Receptor-ligand interactions also regulate 
5-HTT uptake kinetics by interconnecting several signaling pathways. For the details, see the text.
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This process is controlled by functional coupling of activated stromal interaction molecule 1 
(STIM1) to Orai1 [13]. Interestingly, strongly reduced SOCE was found in 5Htt−/− platelets [14]. 
This suggests that secreted platelet 5-HT contributes to the regulation of SOCE through bind-
ing to 5-HT
2A
 which activates Gq-PLCβ-mediated Ca2+ store release, thereby further activating 
STIM1/Orai1 complex. Interestingly, SOCE-induced signal can strongly inhibit 5-HT uptake 
in human platelets via 5-HTT [9, 11]. This could be an important step to keep 5-HT outside 
of platelets, thereby increasing extracellular 5-HT concentration and permanently activating 
5-HT
2A
 on the platelet surface. Therefore, 5-HT cannot enter the platelet cytosol during SOCE. 
Interestingly, 5-HTT contains several consensus sites for PKC. It has been shown that PKC 
activity is required for the internalization of the transporter suggesting a link between 5-HT 
uptake and intracellular Ca2+ level [15–18]. Altogether, Ca2+ signaling, Ca2+ store release, and 
Ca2+ influx through SOCE play an important regulatory role for 5-HT cycling in human and 
mouse platelets.
After Ca2+ store release and PKC activation, integrins exposed and activated on the platelet 
surface support aggregation and thrombus formation. In β3 integrin-deficient platelets, 5-HT 
uptake was strongly reduced, indicating a functional crosstalk between 5-HTT and β3 integ-
rin [19]. Integrin activation defect in response to glycoprotein VI (GPVI) or C-type lectin-like 
receptor 2 (CLEC-2) stimulation was found in 5Htt−/− mouse platelets, which was fully rescued 
in the presence of extracellular 5-HT [14]. The physical interaction between 5-HTT and β3 
seems to be dispensable for β3 integrin activation. The observed integrin activation defect is 
due to the lack of the secreted platelet 5-HT which further amplifies “inside-out” activation of 
integrins through Ca2+-dependent and independent pathways mediated by Ca2+- and DAG-
regulated guanine exchange factor-1 (CalDAG-GEFI) and PKC, respectively.
Although 5-HT is mainly stored in dense granules, intracellular-free 5-HT in the cytoplasm has 
been proposed to activate diverse biological processes called serotonylation. It has been shown 
that small-guanosine triphosphate-binding protein (GTP)-ases covalently bind 5-HT, thereby 
changing the structure and activity of GTPase, leading to α-granule exocytosis from platelets. 
This process requires tissue transglutaminase and factor XIIIa, both activated by mobilized 
Ca2+. Transglutaminase may mediate the transamidation of small GTPases, like cytoplasmic Ras 
homolog gene family member A (RhoA) and a small GTP-binding protein Rab4. Serotonylation 
in turn blocks the inactivation of both molecules. A complex composed of Ca2+ and calmodu-
lin (CaM) may also activate guanine exchange factors (GEFs), which induce the exchange of 
guanosine di- (GDP) to triphosphate (GTP) on RhoA and Rab4 and thus stimulates activation 
of the respective protein. These two active molecules play an important role in cytoskeleton 
rearrangement, exocytosis of α-, and dense granule contents. Some bioactive molecules stored 
in platelet granules, such as fibrinogen and factor V, are also known to be serotonylated [8]. 
Upon platelet activation, these proteins are exposed at the platelet surface and are used to 
mark a subpopulation of highly activated, pro-coagulant platelets, the so-called collagen and 
thrombin-activated (COAT) platelets. Coated platelets express high levels of phosphatidylser-
ine and strongly support prothrombinase activity [8, 20].
Besides the dopamine transporter (DAT), the noradrenaline transporter (NET), and the 
organic transporter (OCT), 5-HTT is an important 5-HT transporter to regulate 5-HT uptake 
from the blood plasma and reuptake of the released platelet 5-HT in certain physiological 
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conditions. 5-HTT is encoded by the SLC6A4 gene containing 14 exons. The protein structure 
of 5-HTT contains 12 transmembrane domains. In humans, the splice variants of 5-HTT and 
their mutations are associated with several pathologies, such as anxiety, suicide, depression, 
substance abuse, autism, and neurogenic disorders [21–24]. 5-HTT is abundantly expressed 
not only on neurons, endothelial cells, mast cells, immune cells, in intestine, and vasculature, 
but also in platelets [25, 26]. It is well established that in platelets 5-HTT plays an important 
role in the uptake of 5-HT from the circulation. Monoamine transporters are thought to be 
able to compensate for one another where they are co-expressed. For example, 5-HT may be 
taken up in venous vessels independently of 5-HTT expression [25, 27]. Interestingly, and in 
sharp contrast to venous vessels, genetic ablation of 5Htt in mice completely abolished 5-HT 
uptake in platelets, since no detectable secreted 5-HT was observed upon platelet activation, 
indicating an essential role of 5-HTT for 5-HT uptake into platelets, which cannot be com-
pensated by other transporters [14]. Altogether, these results highlight the cell-type-specific 
regulation of 5-HT uptake in mammalian cells.
5-HTT can be targeted by several antidepressants, such as selective serotonin reuptake inhibitors 
(SSRIs) (cf., Section 5), which are widely used in the treatment of psychiatric diseases to increase 
5-HTT concentrations in the synaptic space. The blockade of 5-HTT with the SSRI citalopram 
reduces the aggregation response to collagen in human platelets [28] due to reduced phosphory-
lation of a tyrosine-protein kinase Syk in the GPVI signalosome. Syk can also bind and phosphor-
ylate 5-HTT suggesting an Syk-mediated functional crosstalk between 5-HTT and GPVI complex. 
Interestingly, 5Htt−/− mouse platelets could not show any abnormalities in the tyrosine phosphory-
lation cascade of the GPVI signalosome, as Syk phosphorylation was normal after GPVI stimuli. 
Consequently, Syk and 5-HTT interaction seems to be dispensable for the initial activation of 
GPVI complex, but enhanced Syk activity may regulate the 5-HT uptake in platelets [29].
3. Paracrine-regulatory mechanisms of platelet serotonin
During degranulation, activated platelets secrete a significant amount of 5-HT from dense 
granules which is clinically relevant to induce acute thrombotic events [30, 31] by promoting 
vasoconstriction and cellular activation of neighboring platelets and lymphocytes through 
their 5-HT receptors.
5-HT receptors expressed on endothelial, smooth muscle, and immune cells respond to 
platelet-derived 5-HT (Figure 3). 5-HT has growth-promoting effects on endothelial cells, 
which may facilitate tissue healing after vascular damages [32]. However, 5-HT may also 
exert dual effects either stimulating constriction or dilatation of microvasculature. In the liver, 
5-HT appears to mainly promote constriction of hepatic sinusoid vessels, since mice lacking 
peripheral 5-HT display elevated sinusoidal perfusion under physiological and pathological 
conditions [33]. By contrast, platelet-derived 5-HT coordinates the formation of gaps between 
endothelial cells in the joint microvasculature, which in arthritic conditions may contribute to 
inflammation [34]. How these processes are regulated is still not clear but presumably may 
involve differential signaling pathways through specific 5-HT receptors expressed on vascu-
lar endothelial and smooth muscle cells.
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Platelet-derived 5-HT can regulate the function of T- and B-cells, natural killer cells, mono-
cytes, and neutrophils under certain conditions [35–38]. In the spleen, 5-HT increases mono-
cyte differentiation into dendritic cells and early naive T-cell activation via the 5-HT
2A
 receptor 
[38, 39]. Furthermore, it also has been shown that lymphocytic cytokine levels in mice are 
reduced after treatment with SSRI [40]. In a mouse model of viral hepatitis, the release of 5-HT 
by platelets was responsible for tissues damage caused by CD8 (+) T-cells, microcirculatory 
events, and reduced clearance of infiltrated viruses [33]. Moreover, specific antagonism of 
5-HT receptors in mice attenuated asthmatic attacks and sepsis [37, 41].
5-HT released from dense granules upon activation by the inflamed endothelium also con-
tributes to the recruitment of immune cells to the vascular wall [37]. Indeed, platelet-derived 
5-HT promotes leukocyte migration, possibly via activation of endothelial cells, thereby 
enhancing P-selectin exposure and IL-8 release [37], which trigger neutrophil rolling, adhe-
sion, and extravasation. Moreover, locally increased levels of platelet-released 5-HT had 
paracrine effects on endothelial cells, thereby inducing microvasculature leakage through the 
activation of transglutaminase and the phosphorylation of vimentin [42]. By contrast, in solid 
tumors platelet-released 5-HT has been described as a major regulator of the tumor vascular 
homeostasis that continuously prevent bleeding. Interestingly, tumor-infiltrating leukocytes 
have been identified as the cause of tumor bleeding [43, 44]. Altogether, these studies suggest 
that under specific conditions, platelet-released 5-HT promotes clot formation and modulates 
immune cell functions.
Figure 3. Paracrine effects of platelet 5-HT. Secretion of platelet 5-HT modulates the function of endothelial and smooth 
muscle cells either promoting vessel constriction or dilatation. Platelet 5-HT influences several functions of immune 
cells, indicating their importance in the regulation of immune cell response and activities under pathophysiological 
conditions. For the details, see the text.
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In humans, 5-HT levels appear elevated in infection and autoimmune diseases, suggesting that 
SSRI could be applicable for vascular and immune system modulation. Since platelets are the 
major 5-HT store in the blood, pharmacological blockage of 5-HT uptake in platelets increases 
the level of 5-HT in the blood plasma transiently. Unexpectedly, 5Htt−/− mice display reduced 
5-HT levels in plasma [14]. In 5Htt−/− mice, elevated urinary 5-HIAA levels were detected sug-
gesting a faster 5-HT metabolism in the peripheral blood. Consequently, platelet 5-HT uptake 
and storage play an important regulatory role for controlling systemic 5-HT metabolic cycles. 
Future studies are needed to specify the exact mechanisms of platelet-derived 5-HT on vascu-
lar and immune system modulation in normal physiology and diseases.
4. Pathophysiological consequences of abnormal platelet serotonin 
release
5-HT plasma concentration was analyzed in several pathological contexts. It became widely 
recognized that 5-HT is an independent risk factor for platelet aggregation and for throm-
bus formation in animal models (cf., Section 6) and human patients [19, 45–49]. Plasma 5-HT 
can support platelet aggregation and thrombus growth through 5-HT
2A
-dependent or inde-
pendent signaling pathways. Pharmacological blockade of 5-HT
2A
 receptor increases the 
5-HT uptake rates in animal models of hypertension, as well as ex vivo platelet aggregation. 
Vikenes et al. detected a 10-fold increase of plasma 5-HT in patients undergoing angiography 
after admission for myocardial infarction [50]. In these patients, high plasma 5-HT was associ-
ated with cardiac events. In another study, more than 10-fold rise in 5-HT has been noticed in 
coronary vessels of patients following angioplasty. Importantly, in these patients the level of 
5-HT in the systemic plasma was normal [51]. Together, these studies suggest that in vivo the 
interplay between circulating 5-HT and platelet function could be a predictive factor.
5-HT levels are drastically increased during myocardial ischemia, and blockade of the 5-HT
2
 
receptor improves the outcome after myocardial infarction in different mouse models [52, 53]. 
5-HT also enhances the survival of cardiomyocytes via the 5-HT
2B
 receptor. In hepatic ischemia 
models, platelets promote tissue repair [54], and proliferation of hepatocytes was shown to 
be partly mediated by platelet 5-HT after liver ischemia [55]. 5-HT also contributes to intratu-
moral homeostasis by dysbalancing permeability factors [44]. 5-HT-induced growth of human 
hepatocellular carcinoma cells and specific blockade of the 5-HT
2
 receptor decreased recruit-
ment of circulating tumor cells [56, 57]. It has been suggested that the inhibition of platelet 
granule contents might be effective to induce intratumoral bleeding, thereby decreasing tumor 
viability and growth. Additionally, plasma 5-HT levels are increased in patients with colorec-
tal, liver, and intestinal cancers [58, 59].
Allergic airway inflammation provokes a local release of 5-HT in mouse models and human 
patients [41]. Interestingly, after challenge with an allergen, 5-HT increased 10-fold in bron-
cho-alveolar lavage of predisposed patients, inducing asthmatic attacks. In line with these 
studies, 5-HT is known as a key regulator of pulmonary vascular resistance and vessel wall 
integrity [60, 61].
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5. Clinical applications: effects of selective serotonin reuptake inhibitors 
on platelet functions
Selective serotonin reuptake inhibitors are commonly used drugs for the treatment of patients 
with severe depressive and anxiety disorders [62]. SSRIs were developed to selectively inhibit 
the uptake of 5-HT through the 5-HTT transporter in the brain, while having minimal side 
effects on DAT and NET proteins which can also transport 5-HT [63]. The action of SSRIs relies 
on the modulation of the allosteric region of the transporter, thereby leading to a conforma-
tional change and blocking of the uptake of 5-HT [63]. The uptake of 5-HT into neurons is very 
important for the clearance of the synaptic cleft, preventing firing rates and overstimulation 
of receptors [64]. This uptake and the later release are blocked upon treatment with SSRIs, 
such as fluvoxamine, fluoxetine, nortryptiline, citopram, and escitalopram [65]. The different 
SSRIs vary in kinetics being competitive and non-competitive inhibitors. Two distinct binding 
sites on 5-HTT have been identified, a low-affinity allosteric site, mediating the dissociation of 
SSRIs from their high-affinity site, which induces the blockade of 5-HT uptake [64].
There is evidence that targeting 5-HT receptors or using serotonin-like molecules is effective 
in the treatment of non-neuronal diseases. The use of tricyclic antidepressants, but not SSRIs, 
is associated with an increased risk of myocardial infarction. SSRIs have shown no cardiac 
toxicity, even in patients with heart disease. Several epidemiologic studies reported lower 
cardiovascular morbidity and mortality in patients treated with SSRI [66–68].
Depression is a significant risk factor for ischemic heart and cerebrovascular disease as well 
as mortality following myocardial infarction. The potential effects of SSRIs upon the cardio-
vascular system may therefore play an important role. These drugs had potential benefit in 
hypertensive patients after myocardial infarction and hypertensive responses to depression 
were reduced in patients who had been prescribed SSRIs [30]. In blood samples of depres-
sive patients taking fluoxetine, the platelet aggregation response to submaximal collagen 
stimulation was decreased [69]. In this study, a significant decrease in 5-HT concentration 
was observed in platelet-rich plasma associated with the use of fluoxetine but not with the 
tricyclic antidepressant amitryptiline. It is intriguing whether lowered platelet 5-HT content 
translates into less 5-HT release during platelet activation in patients with thrombotic dis-
eases. Enhanced platelet reactivity was observed in patients suffering from depression and 
chronic heart disease due to the upregulated β-thromboglobulin (β-TG) and platelet factor 
4 (PF4) levels [70]. Lowered PF4 and β-TG levels have been observed upon treatment with 
SSRI paroxetine [71], suggesting that reduced platelet aggregation in vivo may impact coro-
nary artery-related mortality. SSRI treatment also decreases platelet reactivity in patients with 
heart failure. Other SSRIs, sertraline, and N-desmethylsertraline were also shown to dampen 
platelet responses [72].
SSRIs have been shown to increase the risk of bleeding in patients with liver cirrhosis and liver 
failure. Importantly, SSRIs may also directly increase gastric acidity with ulcerogenic effect 
resulting in GI bleeding. The risk of SSRI-associated GI bleeding is increased with the con-
current use of nonsteroidal anti-inflammatory drugs, anticoagulants, and antiplatelet agents, 
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and is decreased by concurrent proton pump inhibitors [73, 74]. In conclusion, SSRIs appear 
to be protective against cardiovascular diseases and may enhance the risk for GI bleeding. 
However, to date this evidence is not yet conclusive.
6. Experimental studies on the role of platelet serotonin in arterial 
thrombosis and stroke
Over the past decades, the functions of peripheral 5-HT have received increasing attention. It 
has been shown that peripheral 5-HT plays a major role in a variety of important processes, 
including hemostasis and immune defense. This has been addressed by using Tph1−/− mice, 
which lack peripheral 5-HT in the circulation, due to the lack of the enzyme that converts 
hydroxylases tryptophan to 5-HT in the gut [75]. In humans, abolished or decreased level 
of TPH1 is associated with impulsive behavior, aggression, irritable bowel syndrome, anxi-
ety, and other pathologies [76–79]. Genetic ablation of TPH1 function in mice not only leads 
to several disorders, such as mild anemia, cardiomyopathy, and diabetes, but also to other 
defects in hemostasis, erythropoiesis, pulmonary hypertension, and lung regeneration. The 
lack of 5-HT in this mouse model is associated with decreased neutrophil recruitment to 
inflammatory sites, diabetics, and mild anemia [37, 80].
Recent studies using wild-type mice infused with 5-HT or Tph1−/− mice have demonstrated 
that peripheral 5-HT is required for platelet aggregation [14]. Additionally, in vivo 5-HT infu-
sion generates hyperreactive platelets with reduced bleeding time and shortened occlusion 
time of the carotid arteries in wild-type mice. 5-Htt−/− mice have prolonged bleeding time, 
reflecting the increased bleeding risk described to occur using long-term SSRI treatment in 
human patients. In comparison to this relatively mild hemostatic defect, 5Htt−/− mice were not 
able to form occlusive thrombi in response to mechanical injury of the abdominal aorta as 
compared to wild-type animals [14].
Platelets contribute to the progression of infarct growth after transient brain ischemia by 
thrombo-inflammation with platelet-immune cell interactions. SSRI treatment of stroke 
patients has been described to enhance brain function recovery, indicating a therapeutic ben-
efit of the direct blockade of 5-HTT function. Neuroblast proliferation and cell migration have 
been shown to be enhanced and associated with increased microvessel density during SSRI 
treatment, explaining the possible role of 5-HTT in tissue repair after ischemic insults [81–83]. 
5Htt−/− mice have been studied in the tMCAO (transient intraluminal filament model of mid-
dle cerebral artery occlusion) model of ischemic stroke. Unexpectedly, these mice developed 
similar brain infarcts to wild-type controls and the 5-HTT neurological outcome was indistin-
guishable [14]. In line with this study, SSRI treatment could not reduce infarct size or cerebral 
edema in mice [82], suggesting that this treatment cannot protect neurons or other cells in the 
ischemic brain. Altogether, these results indicate that SSRI treatment may have a long-term 
effect in the ischemic brain tissue which positively influences post-stroke recovery. Further 
investigation is necessary to understand the specific role of peripheral and brain 5-HT in 
thrombo-inflammation during stroke and infarct progression.
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7. Conclusions
5-HT is an ancient molecule that is better known for its functions in the brain than in the 
periphery. However, literature describing the contribution of peripheral 5-HT, including 
platelet 5-HT, is rapidly growing. It became evident that platelet 5-HT has a complex role 
involving many bidirectional interactions with tissue microenvironment to regulate platelet 
and immune cell functions. SSRI treatment in animal models appears to improve thrombotic 
and inflammatory diseases. Further fundamental and preclinical studies are needed for a bet-
ter understanding of platelet 5-HT functions in humans. In conclusion, targeting thrombo-
immune-modulatory functions of platelet serotonin may provide new important therapeutic 
approaches.
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